LivaNova plc — Q1 2021 Form 10-Q Summary
Business context and reporting period
LivaNova is a global medical-device company operating through Cardiovascular and Neuromodulation segments. The filing covers the three months ended March 31, 2021, with comparative results for the three months ended March 31, 2020. Financial statements are unaudited, prepared under U.S. GAAP, and reported in U.S. dollars.
Financial performance and position
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Net sales | $247.6 million | $242.4 million | Up 2.1% |
| Operating income (loss) | $(4.4) million | $0.6 million | Declined |
| Net income (loss) | $(29.7) million | $37.6 million | Declined |
| Diluted EPS | $(0.61) | $0.77 | Declined |
| Cash flow from operations | $19.5 million | $(106.0) million | Improved |
| Capital expenditures | $8.2 million | $8.6 million | Lower |
Gross margin was approximately 68.0%, compared with 71.6% in the prior-year quarter. Operating margin was approximately (1.8)%, compared with 0.3%; net margin was approximately (12.0)%, compared with 15.5%. Cost of sales increased to $79.2 million from $68.9 million, while research and development increased to $44.6 million from $35.9 million. SG&A decreased to $112.6 million from $120.2 million.
At March 31, 2021, cash and cash equivalents were $252.5 million. Total debt obligations were approximately $658.2 million, comprising $11.8 million of current debt and $646.4 million of long-term debt. The company had no borrowings under its $50.0 million revolving credit facility and stated that it was in compliance with applicable financial covenants. Management expects available cash, operating cash flow and borrowing capacity to fund expected needs for the next twelve months.
Material changes versus the prior comparable period
- Cardiovascular sales declined 5.9% to $143.2 million, primarily due to COVID-19-related reductions in cardiac procedures in Europe and the Rest of World. Cardiopulmonary sales decreased 6.6%, and Heart Valve sales decreased 14.9%.
- Advanced Circulatory Support sales increased 23.8% to $13.0 million, supported by LifeSPARC adoption and higher U.S. procedure volumes.
- Neuromodulation sales increased 15.7% to $103.7 million, led by improving market conditions, particularly in the United States and Asia Pacific.
- Segment income decreased 43.5% to $9.0 million. Cardiovascular segment income declined 35.2% to $5.6 million, while Neuromodulation segment income increased 0.5% to $34.0 million.
- Interest expense increased to $15.9 million from $4.8 million following the June 2020 debt transactions. Foreign exchange and other losses increased to $6.4 million from $1.9 million.
- Restructuring expense increased to $6.1 million from $1.6 million, primarily for severance and lease-abandonment costs. Litigation provision expense was $3.0 million versus none in the prior-year quarter.
- The prior-year tax benefit included a $41.3 million CARES Act-related discrete benefit. The Q1 2021 effective tax rate from continuing operations was (10.7%), compared with 744.4% in Q1 2020.
- Operating cash flow improved primarily because Q1 2020 included $115.6 million of 3T litigation settlement payments; Q1 2021 also included a $24.6 million CARES Act tax refund.
Guidance, outlook, risks and unusual items
The filing does not provide clear numerical revenue or earnings guidance. Management reported improving market dynamics in Q1 2021, especially in the United States, and expects recovery to continue as patients return to physician visits and procedure volumes improve. However, COVID-19 case-rate variability and delays in vaccination efforts could materially affect results.
- The Heart Valve business was classified as held for sale following a planned sale for approximately €60.0 million. The company recorded a $180.2 million impairment in Q4 2020 and increased the disposal group’s carrying value by $1.0 million in Q1 2021. The initial closing was expected in the first half of 2021, while the related Saluggia site-management closing could be deferred by up to two years under an April 2021 amended agreement.
- The company recorded a $4.6 million gain from the remeasurement of its Respicardia investment and loan following Zoll Medical’s acquisition of Respicardia; proceeds received in April 2021 were $23.1 million.
- The 3T device product-liability provision was $34.3 million at March 31, 2021. Approximately 85 filed and unfiled claims worldwide were reported as of April 28, 2021, and the company’s actual liability could exceed its estimate.
- The Saluggia hazardous-substances liability was $41.0 million at March 31, 2021. Separately, LivaNova faces potential Italian environmental liabilities for which no provision was recorded because a loss was not considered probable or reasonably estimable; an appellate decision identified potential liability up to the estimated €572.1 million fair value of net assets received in the Sorin spin-off.
- Cash exchangeable senior notes had a March 31, 2021 carrying amount of $215.1 million and mature in December 2025. If exchange conditions are met, cash settlement could adversely affect liquidity and could require current classification.
- Key risks include COVID-19 and procedure volumes, regulatory approvals and compliance, product liability and other litigation, reimbursement changes, foreign exchange and interest-rate exposure, cybersecurity, supply-chain dependence, competition, intellectual-property matters and the company’s ability to meet debt covenants.
Important facts for investors to verify
- Verify the timing, proceeds and final terms of the Heart Valve and Saluggia site-management divestitures.
- Monitor Cardiovascular procedure recovery and Neuromodulation growth as COVID-19 conditions evolve.
- Assess debt service, variable-rate exposure, exchangeable-note cash-settlement risk and compliance with leverage and revenue covenants.
- Track developments in 3T litigation, the Italian environmental proceedings and the Saluggia hazardous-substances obligation.
- Reconcile reported earnings with unusual items, including derivative fair-value movements, restructuring, litigation provisions, disposal-group revaluation and the Respicardia gain.
- Confirm that the company’s stated liquidity outlook remains adequate if operating cash flow weakens or deferred procedures recover more slowly than expected.